---
$id: https://graph.org.ai/products/commodity/51202406
$type: Product
source: UNSPSC
code: "51202406"
title: "Certolizumab pegol"
class: "51202400"
classTitle: "Immunosupressant antibodies"
family: "51200000"
familyTitle: "Immunomodulating drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Certolizumab pegol

**UNSPSC Code**: 51202406
**Class**: [Immunosupressant antibodies](Immunosupressant antibodies.mdx)
**Family**: [Immunomodulating drugs](../Immunomodulating drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a monoclonal antibody, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UMD07X179E. European Medicines Agency schedules Certolizumab pegol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25423. Certolizumab pegol generally arises in the molecular formula C19H30N5O8S(C2H4O)N(C2H4O)N. The term CERTOLIZUMAB PEGOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, No. 3, 2004, list 52.) Most nations, for tariff and trade purposes, schedule certolizumab pegol under HS 30021091 and SITC 54163. Certolizumab pegol bears US NLM identifiers UMLS ID C1872109 and NCI Concept Code C80972. SMILES: As of Q4 2014, CERTOLIZUMAB PEGOL remains US FDA's Preferred Term for this commodity.

